Journal of Surgery Concepts & Practice >
Screening, evaluation and intervention of sarcopenia in older people
SUN Jianqin, YE Mengyao . Screening, evaluation and intervention of sarcopenia in older people[J]. Journal of Surgery Concepts & Practice, 2020 , 25(02) : 114 -119 . DOI: 10.16139/j.1007-9610.2020.02.006
| [1] | Rosenberg IH. Sarcopenia: origins and clinical relevance[J]. J Nutr, 1997, 127(5 Suppl):990s-991s. |
| [2] | Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People[J]. Age Ageing, 2010, 39(4):412-423. |
| [3] | Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age and Ageing, 2019, 48(1):16-31. |
| [4] | Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia[J]. J Am Med Dir Assoc, 2014, 15(2):95-101. |
| [5] | Cao L, Morley JE. Sarcopenia is recognized as an independent condition by an International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) Code[J]. J Am Med Dir Assoc, 2016, 17(8):675-677. |
| [6] | Chen LK, Lee WJ, Peng LN, et al. Recent advances in sarcopenia research in Asia: 2016 update from the Asian Working Group for Sarcopenia[J]. J Am Med Dir Assoc, 2016, 17(8):767.e1-e7. |
| [7] | Dent E, Morley JE, Cruz-Jentoft AJ, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, diagnosis and management[J]. J Nutr Health Aging, 2018, 22(10):1148-1161. |
| [8] | Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico[J]. Am J Epidemiol, 1998, 147(8):755-763. |
| [9] | Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia[J]. J Am Med Dir Assoc, 2011, 12(4):249-256. |
| [10] | Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, confe-rence recommendations, and final estimates[J]. J Gerontol A Biol Sci Med Sci, 2014, 69(5):547-558. |
| [11] | Tessier AJ, Chevalier S. An update on protein, leucine, omega-3 fatty acids, and vitamin D in the prevention and treatment of sarcopenia and functional decline[J]. Nutrients, 2018, 10(8).pii: E1099. doi: 10.3390/nu10081099. |
| [12] | Traylor DA, Gorissen SHM, Phillips SM. Perspective: protein requirements and optimal intakes in aging: are we ready to recommend more than the recommended daily allowance?[J]. Adv Nutr, 2018, 9(3):171-182. |
| [13] | 孙建琴, 张坚, 常翠青, 等. 肌肉衰减综合征营养与运动干预中国专家共识(节录)[J]. 营养学报, 2015, 37(4): 320-324. |
| [14] | Wu H, Xia Y, Jiang J, et al. Effect of beta-hydroxy-beta-methylbutyrate supplementation on muscle loss in older adults: a systematic review and meta-analysis[J]. Arch Gerontol Geriatr, 2015, 61(2):168-175. |
| [15] | Lanza IR, Zabielski P, Klaus KA, et al. Chronic caloric restriction preserves mitochondrial function in senescence without increasing mitochondrial biogenesis[J]. Cell Metabolism, 2012, 16(6):777-788. |
| [16] | Dirks AJ, Leeuwenburgh C. Aging and lifelong calorie restriction result in adaptations of skeletal muscle apoptosis repressor, apoptosis-inducing factor, X-linked inhibitor of apoptosis, caspase-3, and caspase-12[J]. Free Radic Biol Med, 2004, 36(1):27-39. |
| [17] | Wohlgemuth SE, Seo AY, Marzetti E, et al. Skeletal muscle autophagy and apoptosis during aging: effects of calorie restriction and life-long exercise[J]. Exp Gerontol, 2010, 45(2):138-148. |
| [18] | Kunkel SD, Suneja M, Ebert SM, et al. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass[J]. Cell Metab, 2011, 13(6):627-638. |
| [19] | Yu R, Chen JA, Xu J, et al. Suppression of muscle was-ting by the plant-derived compound ursolic acid in a model of chronic kidney disease[J]. J Cachexia Sarcopenia Muscle, 2017, 8(2):327-341. |
| [20] | Varian BJ, Gourishetti S, Poutahidis T, et al. Beneficial bacteria inhibit cachexia[J]. Oncotarget, 2016, 7(11):11803-11816. |
| [21] | Caputi V, Marsilio I, Filpa V, et al. Antibiotic-induced dysbiosis of the microbiota impairs gut neuromuscular function in juvenile mice[J]. Br J Pharmacol, 2017, 174(20):3623-3639. |
| [22] | Buigues C, Fernandez-Garrido J, Pruimboom L, et al. Effect of a prebiotic formulation on frailty syndrome: a randomized, double-blind clinical trial[J]. Int J Mol Sci, 2016, 17(6):pii: E932. doi: 10.3390/ijms17060932. |
| [23] | Ticinesi A, Lauretani F, Milani C, et al. Aging gut microbiota at the cross-road between nutrition, physical frailty, and sarcopenia: is there a gut-muscle axis?[J]. Nutrients, 2017, 9(12): pii: E1303. doi: 10.3390/nu9121303. |
| [24] | Marzetti E, Calvani R, Tosato M, et al. Physical activity and exercise as countermeasures to physical frailty and sarcopenia[J]. Aging Clin Exp Res, 2017, 29(1):35-42. |
| [25] | Peterson MD, Rhea MR, Sen A, et al. Resistance exercise for muscular strength in older adults: a meta-analysis[J]. Ageing Res Rev, 2010, 9(3):226-237. |
| [26] | Law TD, Clark LA, Clark BC. Resistance exercise to prevent and manage sarcopenia and dynapenia[J]. Annu Rev Gerontol Geriatr, 2016, 36(1):205-228. |
| [27] | Lee SJ. Regulation of muscle mass by myostatin[J]. Annu Rev Cell Dev Biol, 2004, 20:61-86. |
| [28] | Murphy KT, Koopman R, Naim T, et al. Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function[J]. FASEB J, 2010, 24(11):4433-4442. |
| [29] | Murphy KT, Ryall JG, Snell SM, et al. Antibody-directed myostatin inhibition improves diaphragm pathology in young but not adult dystrophic mdx mice[J]. Am J Pathol, 2010, 176(5):2425-2434. |
| [30] | Holzbaur EL, Howland DS, Weber N, et al. Myostatin inhibition slows muscle atrophy in rodent models of amyo-trophic lateral sclerosis[J]. Neurobiol Dis, 2006, 23(3):697-707. |
| [31] | Lebrasseur NK, Schelhorn TM, Bernardo BL, et al. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice[J]. J Gerontol A Biol Sci Med Sci, 2009, 64(9):940-948. |
| [32] | Becker C, Lord SR, Studenski SA, et al. Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial[J]. Lancet Diabetes Endocrinol, 2015, 3(12):948-957. |
| [33] | Bhasin S, Calof OM, Storer TW, et al. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging[J]. Nat Clin Pract Endocrinol Metab, 2006, 2(3):146-159. |
| [34] | Sinha-Hikim I, Cornford M, Gaytan H, et al. Effects of testosterone supplementation on skeletal muscle fiber hypertrophy and satellite cells in community-dwelling older men[J]. J Clin Endocrinol Metab, 2006, 91(8):3024-3033. |
| [35] | Onder G, Penninx BW, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study[J]. Lancet, 2002, 359(9310):926-930. |
| [36] | Maggio M, Ceda GP, Lauretani F, et al. Relation of angiotensin-converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects >65 years of age(the InCHIANTI study)[J]. Am J Cardiol, 2006, 97(10):1525-1529. |
/
| 〈 |
|
〉 |
